title: Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity.
abstract: OBJECTIVE
  Statins have beneficial effects in early pre-clinical models of hepatocellular carcinoma (HCC). Our aim was to test the efficacy of pravastatin on the progression of established HCC in rat, and to study its mechanisms.
  
  
  METHODS
  HCC was induced with diethylnitrosamine and N-nitrosomorpholine. After 14 weeks, all rats developed HCC and then received pravastatin or its solvent for 10 weeks (10 rats/group).
  
  
  RESULTS
  Liver tumor mass was lower in pravastatin group (PG) than control group (CG), as estimated from the number of liver tumors (p<0.004) and the liver weight/body weight ratio (p<0.04). Every CG rat surviving at 24 weeks (4/4) had lung metastasis, against only 5/8 in PG. Moreover, the percentage of lung surface occupied by metastasis was 10-fold smaller in PG than CG (p<0.016). Pravastatin decreased liver matrix metalloproteinase (MMP)-9 activity and mostly suppressed MMP-2 activation (p<0.004), likely because it decreased expression of MMP-14 and tissue inhibitor of matrix metalloproteinases-2 (p<0.01), required for MMP-2 activation.
  
  
  CONCLUSIONS
  Pravastatin reduces progression and limits metastatic diffusion of established HCC. This could be linked to the decreased MMP activity. These results, obtained in a very aggressive HCC model, further suggest the potential benefit of statins in human HCC.
authors.affiliation: INSERM E362, Bordeaux F-33076, France.
authors.forename: Danièle
authors.initials: D
authors.lastname: Taras
authors.forename: Jean-Frédéric
authors.initials: JF
authors.lastname: Blanc
authors.forename: Anne
authors.initials: A
authors.lastname: Rullier
authors.forename: Nathalie
authors.initials: N
authors.lastname: Dugot-Senant
authors.forename: Ingrid
authors.initials: I
authors.lastname: Laurendeau
authors.forename: Michel
authors.initials: M
authors.lastname: Vidaud
authors.forename: Jean
authors.initials: J
authors.lastname: Rosenbaum
mesh_terms: D000818:Animals; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000556:secondary; D008175:Lung Neoplasms / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control* / Q000556:secondary; D008297:Male; D053511:Matrix Metalloproteinase 14 / Q000235:genetics; D020778:Matrix Metalloproteinase 2 / Q000235:genetics; D020780:Matrix Metalloproteinase 9 / Q000235:genetics; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000235:genetics*; D017035:Pravastatin / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D053511:Matrix Metalloproteinase 14; D017035:Pravastatin